23
Jun
2021

Third Rock-Backed Abata Secures $95M for T-reg Cell Therapy Against MS

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

All Inclusive Medicine Needs More Diverse Genomic Data
Kidney Companies Taking Pages from Precision Oncology Playbook
Lab Supply Shortages Persist, Slowing Down Everyday Experiments
Bright Peak Therapeutics Raises $107M to Advance Cytokine Engineering